Combined Treatment with Oral Kanamycin and Parenteral Antibiotics for a Case of Persistent Bacteremia and Intestinal Carriage with Campylobacter coli

Okada, Haruka; Kitazawa, Takatoshi; Harada, Sohei; Itoyama, Satoru; Hatakeyama, S.; Ota, Yasuo; Koike, Kazuhiko

doi:10.2169/internalmedicine.47.1161

Cited by 22 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since extraintestinal manifestations are uncommon in campylobacteriosis, data on their antimicrobial therapy are based only on anecdotal case reports (4,18,21) and small retrospective case series (15,16). Thus, the most appropriate protocols for antimicrobial treatment for bacteremic infections, whether caused by susceptible or resistant strains, have not been established.…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial Susceptibilities of Multidrug-Resistant Campylobacter jejuni and C. coli Strains: In Vitro Activities of 20 Antimicrobial Agents

Lehtopolku

Nakari

Kotilainen

et al. 2010

Antimicrob Agents Chemother

View full text Add to dashboard Cite

There is a paucity of information regarding antimicrobial agents that are suitable to treat severe infections caused by multidrug-resistant Campylobacter spp. Our aim was to identify agents that are potentially effective against multiresistant Campylobacter strains. The in vitro activities of 20 antimicrobial agents against 238 Campylobacter strains were analyzed by determining MICs by the agar plate dilution method or the Etest. These strains were selected from 1,808 Campylobacter isolates collected from Finnish patients between 2003 and 2005 and screened for macrolide susceptibility by using the disk diffusion test. The 238 strains consisted of 183 strains with erythromycin inhibition zone diameters of <23 mm and 55 strains with inhibition zone diameters of >23 mm. Of the 238 Campylobacter strains, 19 were resistant to erythromycin by MIC determinations (MIC > 16 g/ml). Given that the resistant strains were identified among the collection of 1,808 isolates, the frequency of erythromycin resistance was 1.1%. All erythromycin-resistant strains were multidrug resistant, with 18 (94.7%) of them being resistant to ciprofloxacin (MIC > 4 g/ml). The percentages of resistance to tetracycline and amoxicillin-clavulanic acid (coamoxiclav) were 73.7% and 31.6%, respectively. All macrolide-resistant strains were susceptible to imipenem, meropenem, and tigecycline. Ten (52.6%) multiresistant strains were identified as being Campylobacter jejuni strains, and 9 (47.4%) were identified as being C. coli strains. These data demonstrate that the incidence of macrolide resistance was low but that the macrolide-resistant Campylobacter strains were uniformly multidrug resistant. In addition to the carbapenems, tigecycline was also highly effective against these multidrug-resistant Campylobacter strains in vitro. Its efficacy for the treatment of human campylobacteriosis should be evaluated in clinical trials.Campylobacteriosis is usually a mild and self-limiting disease requiring no antimicrobial treatment (3, 5). Only rarely is it associated with extraintestinal manifestations, e.g., septicemia, skin and soft tissue infection, infective endocarditis, or meningitis (3). These infections usually require treatment with intravenous antimicrobial agents (3). Infections of immunocompromised patients and pregnant women as well as very young and very old patients or those with persisting symptoms (Ͼ1 week) also require antimicrobial treatment (3). Guillain-Barré syndrome and reactive arthritis are major postinfectious complications of campylobacteriosis (3,24,26).For many years, macrolides and fluoroquinolones have been the first-and second-choice alternatives for the antimicrobial treatment of campylobacter enteritis. Since the late 1980s, however, the emergence of resistance to these antimicrobial groups has complicated the treatment of this disease (1). For example, in Thailand, the rate of resistance to the fluoroquinolones has been up to 80% (8, 14). In Finland, the rate of fluoroquinolone resistance increased between 1995 and 2000 f...

show abstract

Section: Discussionmentioning

confidence: 99%

Antimicrobial Susceptibilities of Multidrug-Resistant Campylobacter jejuni and C. coli Strains: In Vitro Activities of 20 Antimicrobial Agents

Lehtopolku

Nakari

Kotilainen

et al. 2010

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Other therapeutically alternatives include the use of tetracycline, doxycycline, and chloramphenicol. Serious systemic infections are treated with aminoglycosides as gentamicin or even a carbapenem as imipenem (Okada et al 2008). Third generation cephalosporins are not used since they are not effective against Campylobacter (Pacanowski et al 2008).…”

mentioning

confidence: 99%

Antimicrobial Resistance in Campylobacter spp.

Lapierre

Arias

Fernández

2016

Campylobacter Spp. And Related Organisms in Poultry

View full text Add to dashboard Cite

The resistance of infectious agents to a broad range of antimicrobial drugs is a growing public health problem, which raises significant social concerns. This chapter describes the main antimicrobial resistance problems in developed and developing countries and the possible relationship between the resistances of Campylobacter strains found in poultry and humans. Determining the level of the problem is essential for control, formulating, and monitoring an effective response to antimicrobial resistance.

show abstract

“…[4–6,13] In accordance with these findings, humoral immunity seems to play a role in immunity against and eradication of Campylobacter spp. [5] Secretory IgA in the intestinal mucosa may act as an important local immune defense; however, there was no significant increase in Campylobacter infections in patients with selective IgA deficiency.…”

Section: Discussionmentioning

confidence: 68%

“…[17] Other examples include erythromycin given for 6 weeks to eradicate Campylobacters , [5] clarithromycin given for 3 weeks in a patient with C. jejuni bacteremia, [18] and oral kanamycin in patients with recurrent C. coli bacteremia. [6,19] Our patient received aminoglycosides at the time of each admission. First-generation cephalosporins, which almost all C. jejuni strains are resistant to, [11,20] were concomitantly administered, and the duration of antibiotic therapy in each bacteremia episode was less than 2 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…is the most common cause of infectious diarrhea in patients with hypogammaglobulinemia, [3] and cases of recurrent bacteremia associated with C. coli and C. lari , as well as C. jejuni have been reported in patients with hypogammaglobulinemia. [4–6] In spite of this, an antibiotic treatment strategy for immunocompromised patients experiencing recurrent Campylobacter infections has not been established, and no study on the prevention of recurrent Campylobacter infections has been implemented.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recurrent Campylobacter jejuni bacteremia in a patient with hypogammaglobulinemia

Kim

Shin²,

Han³

et al. 2017

Medicine

View full text Add to dashboard Cite

Rationale:Although some cases of recurrent bacteremia due to Campylobacter jejuni have been reported in immunocompromised patients, antibiotic treatment strategies to eradicate C. jejuni and prevent recurrent infections in immunocompromised patients have not been established. Authors’ experience of such rare cases should be shared for improving patients’ outcomes.Patient concerns:An 18-year-old boy with hypogammaglobulinemia, who received intravenous immunoglobulin replacement therapy every 3 weeks, was admitted to hospital repeatedly due to recurrent diarrhea and cellulitis of the leg.Diagnoses:The patient was admitted 6 times, and among them, C. jejuni was isolated from blood cultures 4 times and stool cultures 2 times.Interventions:The patient experienced recurrent C. jejuni enteritis and bacteremia 5 times despite macrolide therapy. Doxycycline was administered for 3 months after the fifth admission.Outcomes:Ten months after the completion of doxycycline therapy for 3 months, C. jejuni enteritis relapsed; however, since then, recurrent infection has not occurred for 10 months.Lessons:Immunocompromised patients can experience recurrent C. jejuni infection despite prolonged antibiotic therapy. Further studies to establish appropriate antibiotic therapy for eradicating colonized C. jejuni and preventing recurrent infection are needed.

show abstract

Combined Treatment with Oral Kanamycin and Parenteral Antibiotics for a Case of Persistent Bacteremia and Intestinal Carriage with Campylobacter coli

Abstract: Campylobacter coli (C. coli

Cited by 22 publications

References 18 publications

Antimicrobial Susceptibilities of Multidrug-Resistant Campylobacter jejuni and C. coli Strains: In Vitro Activities of 20 Antimicrobial Agents

Antimicrobial Susceptibilities of Multidrug-Resistant Campylobacter jejuni and C. coli Strains: In Vitro Activities of 20 Antimicrobial Agents

Antimicrobial Resistance in Campylobacter spp.

Recurrent Campylobacter jejuni bacteremia in a patient with hypogammaglobulinemia

Contact Info

Product

Resources

About